ストックスクリーナーアプリを入手
90.18
1.08%
-0.82
前日終値:
$91.00
開ける：
$89.74
24時間の取引高:
102.98K
Relative Volume:
0.13
時価総額：
$6.01B
収益：
$189.76M
当期純損益:
$-196.54M
株価収益率:
-29.01
EPS:
-3.1087
ネットキャッシュフロー:
$-156.63M
1週間 パフォーマンス:
-8.21%
1か月 パフォーマンス:
-13.33%
6か月 パフォーマンス:
-11.85%
1年 パフォーマンス:
+69.95%
1日の値動き範囲:
$89.12
$91.47
1週間の範囲:
$87.19
$97.81
52週間の値動き範囲:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
名前
Rhythm Pharmaceuticals Inc
セクター
電話
857-264-4280
住所
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
89.99 | 6.07B | 189.76M | -196.54M | -156.63M | -3.1087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.37 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.63 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.83 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-11-25 | 開始されました | Citigroup | Buy |
| 2025-11-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-07-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2025-01-02 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Guggenheim | Buy |
| 2024-09-18 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-08-08 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-05 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 繰り返されました | Needham | Buy |
| 2022-03-02 | 再開されました | Stifel | Buy |
| 2022-02-17 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 再開されました | Goldman | Neutral |
| 2021-08-04 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-08-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-01-08 | 開始されました | Goldman | Sell |
| 2019-07-12 | アップグレード | Stifel | Hold → Buy |
| 2019-07-08 | 開始されました | Canaccord Genuity | Buy |
| 2019-03-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-09-07 | 再開されました | Morgan Stanley | Overweight |
| 2018-06-25 | 繰り返されました | Needham | Buy |
| 2018-06-15 | 繰り返されました | Needham | Buy |
| 2017-10-30 | 開始されました | BofA/Merrill | Buy |
| 2017-10-30 | 開始されました | Needham | Buy |
すべてを表示
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Rhythm Pharmaceuticals (RYTM) Is Down 8.2% After Positive TRANSCEND Data And FDA sNDA Progress - simplywall.st
Proposed sale of 64,540 common shares under registered plan (RYTM) - Stock Titan
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals (RYTM) CAO exercises RSUs, withholds shares for taxes - Stock Titan
Jefferies reiterates Rhythm Pharmaceuticals stock rating on trial outlook By Investing.com - Investing.com Canada
RYTM (NASDAQ: RYTM) brokered notice for 35,460-share sale on 03/03/2026 - Stock Titan
Does Rhythm Pharmaceuticals (RYTM) Share Price Reflect Its Obesity Treatment Potential Today - simplywall.st
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) CFO exercises options, acquiring 6,099 shares - Stock Titan
Canaccord Genuity Lowers Price Target for RYTM, Maintains Buy Ra - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $140.00 at Canaccord Genuity Group - MarketBeat
HC Wainwright Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $110.00 - MarketBeat
RYTM: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus
Why Is Rhythm Pharmaceuticals Stock Trading Higher Today?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Robust Analyst Ratings Signal Potential 51.69% Upside - DirectorsTalk Interviews
Canaccord lowers Rhythm Pharmaceuticals stock price target to $140 - Investing.com
Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction - marketscreener.com
Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity - TipRanks
Rhythm Pharmaceuticals posts 18.8% placebo‑adjusted BMI reduction in TRANSCEND Phase 3 52‑week data - TradingView
Rhythm Pharmaceuticals (Nasdaq: RYTM) adds positive Phase 3 HO data ahead FDA PDUFA - Stock Titan
Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential - Sahm
Rhythm Pharmaceuticals (RYTM) Reveals Promising Phase 3 Trial Da - GuruFocus
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price - Yahoo Finance
Rhythm Pharmaceuticals says PDUFA goal date for setmelanotide is March 20, 2026 - marketscreener.com
Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026 - TradingView
Obesity drug shows 18.8% BMI edge, backing first FDA bid in acquired HO - Stock Titan
Artisan Partners Limited Partnership Buys 62,362 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
RYTM SEC FilingsRhythm Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Rhythm Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-02-27 - Seeking Alpha
Wells Fargo & Company Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $136.00 - MarketBeat
Rhythm Pharmaceuticals (RYTM) Price Target Lowered by Wells Farg - GuruFocus
RBC Capital Adjusts Price Target on Rhythm Pharmaceuticals to $140 From $145, Maintains Outperform Rating - marketscreener.com
Citizens Jmp Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $176.00 - MarketBeat
Is Rhythm Pharmaceuticals Inc. stock risky to hold now2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Needham & Company LLC Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
RYTM Stock Update: Guggenheim Maintains 'Buy', Raises Price Targ - GuruFocus
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Guggenheim raises Rhythm Pharmaceuticals stock price target on guidance By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Citizens raises Rhythm Pharmaceuticals stock price target on HO approval outlook - Investing.com Nigeria
Rhythm Pharmaceuticals (RYTM) Financials 2026Income Statement and Balance Sheet - MarketBeat
Decoding Rhythm Pharmaceuticals Inc (RYTM): A Strategic SWOT Ins - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Rhythm Pharmaceuticals files for mixed shelf - marketscreener.com
Rhythm Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock. - Bitget
Rhythm Pharmaceuticals Files For Mixed Shelf - TradingView
Rhythm Pharmaceuticals Inc (RYTM) Q4 2025 Earnings Call Highligh - GuruFocus
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target - Investing.com Nigeria
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target By Investing.com - Investing.com India
Rhythm Pharmaceuticals Inc (RYTM) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
大文字化:
|
ボリューム (24 時間):